Medexus Pharmaceuticals Inc.

Medexus Pharmaceuticals Inc.

4.01
USD
+0.19
(+5.08%)
-0.04EPS
108.80MMarket Cap
Feb 10Next Earn

Total Valuation

USD

As of September 30, 2026, Medexus Pharmaceuticals Inc carries a market capitalization of 108.80M, placing it among publicly traded companies globally. Its enterprise value stands at 126.67M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap108.80M
Enterprise Value126.67M

Important Dates

Medexus Pharmaceuticals Inc's next confirmed earnings release is scheduled for February 10, 2027.

Earnings Date2/10/2027

Share Statistics

As of September 30, 2026, Medexus Pharmaceuticals Inc has 31.43M shares outstanding.

Shares Outstanding31.43M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 1.03, and the price-to-book ratio stands at 2.24.

PS Ratio1.03
PB Ratio2.24
P/TBV Ratio-5.17
P/FCF Ratio91.88
P/OCF Ratio6.78

Enterprise Valuation

As of September 30, 2026, Medexus Pharmaceuticals Inc trades at an EV/EBITDA multiple of 7.38 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.97 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 126.67M versus a market cap of 108.80M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.18
EV / EBITDA7.38
EV / EBIT16.97

Financial Position

As of September 30, 2026, Medexus Pharmaceuticals Inc maintains a current ratio of 1.27, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 54.02, indicating elevated leverage, while an interest coverage ratio of 3.49 demonstrates adequate ability to service its debt obligations.

Current Ratio1.27
Quick Ratio0.43
Debt / Equity54.02
Debt / EBITDA1.53
Interest Coverage3.49

Financial Efficiency

USD

Over the twelve months ended September 30, 2026, Medexus Pharmaceuticals Inc posted a negative return on equity (ROE) of -2.45, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -0.83, reflecting losses generated across the asset base. The company generates approximately 1.19M in revenue per employee across its workforce of 90.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.42 indicates how many times Medexus Pharmaceuticals Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-2.45
Return on Assets (ROA)-0.83
Revenue Per Employee1.19M
Employee Count90.25
Inventory Turnover1.42

Taxes

USD

Over the twelve months ended September 30, 2026, Medexus Pharmaceuticals Inc recorded 400,000.00 in income tax expense. The company reported a pretax loss of -838,000.00 and -1.24M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax400,000.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Medexus Pharmaceuticals Inc's stock has gained approximately 115.70% over the past 52 weeks. The 50-day moving average sits at 3.57, while the 200-day moving average is 3.04.

52-Week Price Change115.70%
50-Day Moving Average3.57
200-Day Moving Average3.04

Income Statement

USD

Over the twelve months ended September 30, 2026, Medexus Pharmaceuticals Inc generated 107.66M in revenue and converted that into -1.24M in net income, yielding earnings per share of -0.04. EBITDA reached 17.17M, while operating income came in at 7.89M.

Revenue107.66M
Gross Profit59.03M
Operating Income7.89M
Pretax Income-838,000.00
Net Income-1.24M
EBITDA17.17M
EBIT7.46M
Earnings Per Share (EPS)-0.04

Balance Sheet

USD

As of September 30, 2026, Medexus Pharmaceuticals Inc holds 8.35M in cash and equivalents against 26.22M in total debt, resulting in a net debt position of 17.87M. Total book value stands at 48.55M, with working capital of 13.97M providing operational flexibility.

Cash & Cash Equivalents8.35M
Total Debt26.22M
Net Debt17.87M
Equity (Book Value)48.55M
Book Value Per Share1.54
Working Capital13.97M

Cash Flow

USD

Medexus Pharmaceuticals Inc produced 16.30M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -15.07M in capital expenditures, free cash flow totaled 1.22M - equivalent to 0.04 per share.

Operating Cash Flow16.30M
Capital Expenditures-15.07M
Free Cash Flow1.22M
FCF Per Share0.04

Margins

Over the twelve months ended September 30, 2026, Medexus Pharmaceuticals Inc posted a gross margin of 54.83, reflecting its pricing power and cost economics. The operating margin of 7.32 and net profit margin of -1.15 provide insight into operational efficiency.

Gross Margin54.83
Operating Margin7.32
Pretax Margin-0.78
Profit Margin-1.15
EBITDA Margin15.95

Dividends & Yields

Over the twelve months ended September 30, 2026, Medexus Pharmaceuticals Inc paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 1.09, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.10, meaning Medexus Pharmaceuticals Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-0.10
FCF Yield1.09

Stock Splits

Medexus Pharmaceuticals Inc's most recent stock split took place on January 7, 2019 with a 15:1 split ratio.

Last Split Date1/7/2019
Split Ratio15:1

Scores

As of September 30, 2026, Medexus Pharmaceuticals Inc has an Altman Z-Score of 1.45, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.45